TrialNeuro-oncology2016

Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio.

Olivier L Chinot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.